Clinical safety and pharmacokinetics of a novel oral niclosamide formulation compared with marketed niclosamide chewing tablets in healthy volunteers: A three-part randomized, double-blind, placebo-controlled trial.
<h4>Aim</h4>Niclosamide is an established anthelmintic substance and a promising candidate for treating cancer, viral infections, and other diseases. However, its solubility in aqueous media is low, and the systemic bioavailability of the commercially available chewing tablet is poor, li...
Saved in:
| Main Authors: | Niklas Walther, Robert Schultz-Heienbrok, Heino Staß, Victor M Corman, Nils C Gassen, Marcel A Müller, Christian Drosten, Martin Witzenrath, Hweeling Lee, Maximilian G Posch |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0303924 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of niclosamide and ivermectin suspension preparations in sheep parasitoses
by: Victor A. Marchenko, et al.
Published: (2024-04-01) -
A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19
by: Jung Ho Kim, et al.
Published: (2025-08-01) -
Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects.
by: Andreas Jurgeit, et al.
Published: (2012-01-01) -
Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.
by: Rui Li, et al.
Published: (2013-01-01) -
Colistin-niclosamide effervescent dry suspension combats colistin-resistant Salmonella in vitro and in vivo
by: Junkai Zhang, et al.
Published: (2024-12-01)